Market Place
Sourcing Support
All News #Library
Rare Diseases
Ojemda Approved 1st EU Targeted Therapy in Pediatric LLG Glioma
22 Apr 2026 //
GLOBENEWSWIRE
Ipsen Receives Positive CHMP Opinion for Ojemda
27 Feb 2026 //
GLOBENEWSWIRE
Quotient Sciences Extends Mfg Partnership For Ultra-Rare Disease
27 Feb 2026 //
PRESS RELEASE
FDA Grants Ipsen BTD for IPN60340 in Acute Myeloid Leukemia
13 Jan 2026 //
GLOBENEWSWIRE
Ipsen Fails to Land Pivotal Rare Disease Trial
20 Dec 2025 //
FIERCE BIOTECH
Bylvay Gets Japan Approval for Rare Liver Disease PFIC
19 Sep 2025 //
GLOBENEWSWIRE
Health Canada Approves Bylvay for Alagille Syndrome Treatment
09 Sep 2025 //
PR NEWSWIRE
Elafibranor Shows Safety, Efficacy in Rare Liver Disease (PSC) Trial
24 Apr 2025 //
GLOBENEWSWIRE
UK MHRA Grants Approval For Ipsen’s Elafibranor Treatment
10 Oct 2024 //
PHARMABIZ
Ipsen picks up EU approvals for rare disease meds Kayfanda
24 Sep 2024 //
GLOBENEWSWIRE
Ipsen`s Kayfanda Approved In EU For Alagille Syndrome Pruritus
23 Sep 2024 //
GLOBENEWSWIRE
Gilead, Ipsen build the case for their PBC drugs at EASL
05 Jun 2024 //
PHARMAPHORUM
Ipsen matches rare disease and TikTok influencers to create connections
26 Apr 2024 //
ENDPTS
Ipsen confirms U.S. FDA grants priority review for NDA for elafibranor
07 Dec 2023 //
GLOBENEWSWIRE
US FDA approves French drugmaker Ipsen`s rare bone disorder drug
17 Aug 2023 //
REUTERS
FDA reviewers on Ipsen`s potential ultra-rare disease drug
27 Jun 2023 //
ENDPTS
FDA agrees to give Ipsen`s rare disease drug another look
17 Mar 2023 //
FIERCE BIOTECH
Ipsen completes acquisition of Albireo, expanding the scope of Rare Disease
02 Mar 2023 //
GLOBENEWSWIRE
Ipsen’s rare disease drug palovarotene knocked back in EU
28 Jan 2023 //
BUSINESSWIRE
Failed deal, bidding war paved the way for Ipsen`s $952M rare disease buyout
24 Jan 2023 //
ENDPTS
Ipsen to Acquire Albireo Accelerating Growth in Rare Disease
09 Jan 2023 //
BUSINESSWIRE
Ipsen`s rare disease med palovarotene faces another delay
26 Oct 2022 //
FIERCEBIOTECH
Ipsen faces yet another delay for rare disease drug in US
26 Oct 2022 //
PHARMAPHORUM
FDA plans Halloween adcomm for Ipsen’s second chance at rare disease drug
22 Aug 2022 //
ENDPTS
Ipsen to present insights at ASBMR for potential treatment of ultra-rare disease
10 Sep 2020 //
PRESS RELEASE
Spark, Ipsen and more join Rare Disease Day 2020 efforts
29 Feb 2020 //
FIERCE PHARMA
Tiburio Therapeutics to Develop Treatments for Rare NETs and Endocrine Diseases
03 Jan 2019 //
BUSINESSWIRE
Japanese regulators grant additional approval for the sale of Ipsen`s
04 Jul 2017 //
BIOSPECTRUM
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.